Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial
Nanfang Hospital · Southern Medical University · +9 more institutions
Indexed incrossrefpubmed
Abstract
Objective
To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in participants with metabolic dysfunction-associated steatohepatitis (MASH).
Design
Multicentre, double blind, randomised, placebo controlled trial.
Citation impact
74
total citations
- FWCI
- 78.20
- Percentile
- 100%
- References
- 36
Citations per year
Authors
27- JLJiayang LinCorresponding
Nanfang Hospital, Southern Medical University
- YHYan Huang
Southern Medical University
- BXBingyan Xu
Nanfang Hospital, Southern Medical University
- XGXuejiang Gu
Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University
- JHJunlin Huang
Nanfang Hospital, Southern Medical University
Topics & keywords
Topics
Keywords
- Dapagliflozin
- Medicine
- Placebo
- Internal medicine
- Steatohepatitis
- Clinical endpoint
- Confidence interval
- Fatty liver
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- NNNational Natural Science Foundation of ChinaAwards: U22A20288, LC2019ZD010, 2019CR022, 82325011
- SMSouthern Medical UniversityAwards: LC2019ZD010, 2018YFA0800404, 2019CR022
- NSNational Science and Technology Major Project
- NSNational Science Fund for Distinguished Young ScholarsAwards: 82325011, U22A20288